Tobias Dittrich

708 total citations
27 papers, 439 citations indexed

About

Tobias Dittrich is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Tobias Dittrich has authored 27 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Genetics and 9 papers in Hematology. Recurrent topics in Tobias Dittrich's work include Amyloidosis: Diagnosis, Treatment, Outcomes (16 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (6 papers). Tobias Dittrich is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (16 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (6 papers). Tobias Dittrich collaborates with scholars based in Germany, United Kingdom and United States. Tobias Dittrich's co-authors include Stefan Schönland, Ute Hegenbart, Christoph Kimmich, Anna Jauch, Hartmut Goldschmidt, Anthony D. Ho, Tilmann Bochtler, Carsten Müller‐Tidow, Dirk Hose and Anja Seckinger and has published in prestigious journals such as Blood, International Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Tobias Dittrich

23 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tobias Dittrich Germany 12 385 167 125 115 78 27 439
Yoshitaka Sunami Japan 10 246 0.6× 307 1.8× 39 0.3× 263 2.3× 28 0.4× 18 449
Philip R. Greipp United States 7 163 0.4× 85 0.5× 117 0.9× 201 1.7× 27 0.3× 8 324
Tetsuichi Yoshizato Japan 10 201 0.5× 131 0.8× 37 0.3× 312 2.7× 13 0.2× 29 476
Yoko Edahiro Japan 11 299 0.8× 472 2.8× 38 0.3× 356 3.1× 31 0.4× 51 593
Miriam Hobbs United States 7 129 0.3× 75 0.4× 80 0.6× 139 1.2× 11 0.1× 26 225
Ronan Chaligné France 8 223 0.6× 324 1.9× 45 0.4× 296 2.6× 9 0.1× 12 439
Fernando Escalante Spain 10 171 0.4× 84 0.5× 120 1.0× 236 2.1× 10 0.1× 36 325
Cassandra P. Loren United States 7 111 0.3× 96 0.6× 50 0.4× 196 1.7× 15 0.2× 8 342
Juliana Leslie United States 6 280 0.7× 114 0.7× 40 0.3× 170 1.5× 16 0.2× 7 471
Carlos Hader United States 5 67 0.2× 114 0.7× 53 0.4× 215 1.9× 31 0.4× 7 299

Countries citing papers authored by Tobias Dittrich

Since Specialization
Citations

This map shows the geographic impact of Tobias Dittrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Dittrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Dittrich more than expected).

Fields of papers citing papers by Tobias Dittrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Dittrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Dittrich. The network helps show where Tobias Dittrich may publish in the future.

Co-authorship network of co-authors of Tobias Dittrich

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Dittrich. A scholar is included among the top collaborators of Tobias Dittrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Dittrich. Tobias Dittrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bugaj, Till Johannes, Joachim Wiskemann, Bernd Alt‐Epping, et al.. (2025). Biopsychosoziales Belastungsscreening für Patient*innen am Nationalen Centrum für Tumorerkrankungen Heidelberg. 31(3). 320–327.
3.
Dugas, Martin, Tobias Dittrich, Fleur Fritz, et al.. (2024). Next-generation study databases require FAIR, EHR-integrated, and scalable Electronic Data Capture for medical documentation and decision support. npj Digital Medicine. 7(1). 10–10. 9 indexed citations
4.
Dittrich, Tobias, et al.. (2023). Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells. STAR Protocols. 4(3). 102373–102373. 1 indexed citations
5.
Dittrich, Tobias, Martin Schorb, Niels Weinhold, et al.. (2023). High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders. Leukemia. 37(12). 2468–2478. 2 indexed citations
6.
Dittrich, Tobias, Martin Schorb, Isabella Haberbosch, et al.. (2022). A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma. Cell Reports Methods. 2(11). 100322–100322. 4 indexed citations
7.
Basset, Marco, Christoph Kimmich, Nicholas Schreck, et al.. (2021). Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up. British Journal of Haematology. 195(2). 230–243. 11 indexed citations
8.
Kimmich, Christoph, Tobias Terzer, Axel Benner, et al.. (2020). Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 135(18). 1517–1530. 61 indexed citations
9.
Dittrich, Tobias, Christoph Kimmich, Ute Hegenbart, & Stefan Schönland. (2020). Prognosis and Staging of AL Amyloidosis. Acta Haematologica. 143(4). 388–400. 30 indexed citations
10.
Basset, Marco, Christoph Kimmich, Tobias Dittrich, et al.. (2020). Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone. Blood. 136(Supplement 1). 17–18.
11.
Dittrich, Tobias, Axel Benner, Christoph Kimmich, et al.. (2019). Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica. 104(7). 1451–1459. 33 indexed citations
12.
Seckinger, Anja, Jens Hillengaß, Martina Emde, et al.. (2018). CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Frontiers in Immunology. 9. 1676–1676. 32 indexed citations
13.
Kriegsmann, Katharina, Tobias Dittrich, Brigitte Neuber, et al.. (2018). Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. Cytometry Part B Clinical Cytometry. 94(5). 767–776. 11 indexed citations
14.
Manwani, Richa, Ute Hegenbart, Shameem Mahmood, et al.. (2018). Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer Journal. 8(11). 101–101. 24 indexed citations
15.
Kimmich, Christoph, Stefan Schönland, Anthony D. Ho, et al.. (2017). Daratumumab Monotherapy in Thirty-Two Heavily Pre-Treated Patients with Advanced Systemic Light-Chain Amyloidosis. Blood. 130. 1837–1837. 10 indexed citations
16.
Kimmich, Christoph, Stefan Schönland, Mindaugas Andrulis, et al.. (2017). Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid. 24(1). 52–59. 17 indexed citations
17.
Lisenko, Katharina, Fabienne McClanahan, Tilman Schöning, et al.. (2016). Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. BMC Cancer. 16(1). 267–267. 8 indexed citations
18.
Lisenko, Katharina, Fabienne McClanahan, Tilman Schöning, et al.. (2015). Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma. Blood. 126(23). 1506–1506.
19.
20.
Wobus, Manja, Tobias Dittrich, Karin Kast, et al.. (2014). Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. International Journal of Cancer. 136(1). 44–54. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshitaka Sunami Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Tetsuichi Yoshizato Breakdown of academic impact, for papers by Yoko Edahiro Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Ronan Chaligné Breakdown of academic impact, for papers by Fernando Escalante Breakdown of academic impact, for papers by Cassandra P. Loren Breakdown of academic impact, for papers by Juliana Leslie Breakdown of academic impact, for papers by Carlos Hader
Rankless by CCL
2026